Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient’s mucosa

• Published in: World journal of microbiology & biotechnology 2019-03, Vol.35 (3), p.45-9, Article 45
• Main Authors: Simčič, Saša, Berlec, Aleš, Stopinšek, Sanja, Štrukelj, Borut, Orel, Rok
• Format: Article
• Language: English
• Subjects: Adolescent; Anti-Inflammatory Agents - metabolism; Anti-Inflammatory Agents - therapeutic use; Applied Microbiology; Binding; Biochemistry; Biomedical and Life Sciences; Biotechnology; Child; Cytokines; Cytokines - genetics; Cytokines - metabolism; Cytokines - therapeutic use; Dysbacteriosis; Dysbiosis; E coli; Environmental Engineering/Biotechnology; Enzyme-linked immunosorbent assay; Escherichia coli - genetics; Escherichia coli - metabolism; Female; Gastrointestinal Microbiome; Genetic Engineering; Humans; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - microbiology; Interleukin 10; Interleukin 23; Interleukin-10 - genetics; Interleukin-10 - metabolism; Interleukin-23 - genetics; Interleukin-23 - metabolism; Intestinal microflora; Intestinal Mucosa - microbiology; Intestine; Lactococcus lactis; Lactococcus lactis - genetics; Lactococcus lactis - metabolism; Life Sciences; Male; Microbiology; Microbiota; Mucosa; Patients; Probiotics; Probiotics - pharmacology; Recombinant Proteins - genetics; Short Communication; Tumor Necrosis Factor-alpha - genetics; Tumor Necrosis Factor-alpha - metabolism; Tumor Necrosis Factor-alpha - therapeutic use; Tumor necrosis factor-α; Young Adult
• ISSN: 0959-3993; 1573-0972
• DOI: 10.1007/s11274-019-2615-z

Dysbiosis of intestinal microbiota and aberrant inflammatory responses in gastrointestinal mucosa plays important roles in the development of inflammatory bowel disease (IBD). The purpose of this study was to demonstrate the probiotic activity of Lactococcus lactis and the ability of TNF-α-binding by recombinant L. lactis bearing TNF-α-binding affibodies. Various concentrations of recombinant L. lactis were exposed to TNF-α and its binding measured by ELISA. Mucosal biopsies of patients with active IBD were incubated with various L. lactis strains or E. coli DH5α strain and concentrations of TNF-α, IL-23, and IL-10 in the supernatants determined by ELISA. Recombinant L. lactis , at 1 × 10 9 and 1 × 10 8 CFU/mL, bound 22.6% and 18.4%, respectively of TNF-α (p